This review highlights the approval of resmetirom and other hepatoprotective drugs for MASLD management, suggesting a new era in treatment.
Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a major public health concern. Recently, the development of liver-targeted pharmacologic therapies has gained momentum, culminating in the conditional approval of resmetirom which has generated renewed optimism for the management of MASLD. In addition, several other investigational agents have shown promising results in clinical trials.
No takes yet. Share an insight, caveat, or question.
Kaya et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: